245. プロピオン酸血症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 13 / 薬物数 : 16 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
BBP-671
CoA Therapeutics, Inc., a BridgeBio company
2021 Phase 1 NCT04836494 United States;
CX-016492
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
CX-017950
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
Carbaglu
Mendel Tuchman
2012 Phase 2 NCT01599286 United States;
Carglumic Acid (Carbaglu®)
National Taiwan University Hospital
2019 - NCT04284917 Taiwan;
Disodium citrate
Nicola Longo
2008 Phase 1 NCT00645879 United States;
Glutamine
Nicola Longo
2008 Phase 1 NCT00645879 United States;
HST5040
HemoShear Therapeutics
2021 Phase 2 NCT04732429 United States;
MRNA-3927
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
ModernaTX, Inc.
2021 Phase 1/Phase 2 NCT05130437 Canada;United Kingdom;United States;
2021 Phase 1/Phase 2 NCT04159103 Canada;United Kingdom;United States;
Ornithine alpha ketoglutarate
Nicola Longo
2008 Phase 1 NCT00645879 United States;
CoA Therapeutics, Inc., a BridgeBio company
2021 Phase 1 NCT04836494 United States;
CX-016492
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
CX-017950
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
Carbaglu
Mendel Tuchman
2012 Phase 2 NCT01599286 United States;
Carglumic Acid (Carbaglu®)
National Taiwan University Hospital
2019 - NCT04284917 Taiwan;
Disodium citrate
Nicola Longo
2008 Phase 1 NCT00645879 United States;
Glutamine
Nicola Longo
2008 Phase 1 NCT00645879 United States;
HST5040
HemoShear Therapeutics
2021 Phase 2 NCT04732429 United States;
MRNA-3927
ModernaTX, Inc
2020 Phase 1;Phase 2 EUCTR2019-003529-36-GB Canada;United Kingdom;United States;
ModernaTX, Inc.
2021 Phase 1/Phase 2 NCT05130437 Canada;United Kingdom;United States;
2021 Phase 1/Phase 2 NCT04159103 Canada;United Kingdom;United States;
Ornithine alpha ketoglutarate
Nicola Longo
2008 Phase 1 NCT00645879 United States;